Horich William Todd, Senior Vice President of Commercial Operations at Supernus Pharmaceuticals, has reported a series of significant stock transactions following the company's recent merger with Indivior Pharmaceuticals. These transactions, detailed in a recent SEC filing, underscore the impact of the merger on executive compensation and stock ownership structures.

Supernus Pharmaceuticals, Inc., categorized under the SIC code for Pharmaceutical Preparations, is a company that specializes in developing and marketing innovative products for the treatment of central nervous system disorders. The company operates primarily from its headquarters in Rockville, Maryland. Recent filings include a Form 3 on November 4, 2026, and a Form 4 on November 2, 2026, which reported Todd's stock transactions.

The SEC filing reveals that Todd engaged in multiple transactions involving Restricted Stock Units (RSUs) and Performance Share Units (PSUs) on November 2, 2026. Specifically, he disposed of 100,000 RSUs and 5,000 PSUs, among other equity awards, as part of the merger agreement with Indivior. The filing states, "Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior and automatically converted into a corresponding Supernus, Inc. equity award." This conversion was executed at an exchange ratio of 1.5401, reflecting the terms of the merger.

These stock transactions may affect various stakeholders, including shareholders, employees, and industry competitors. As Supernus navigates its new structure post-merger, the decisions made by its executives will be closely watched by investors and analysts alike. The merger with Indivior represents a strategic move in the pharmaceutical sector, aiming to enhance product offerings and market reach.

The filing does not specify what actions will follow these transactions, leaving stakeholders to speculate on the future direction of Supernus Pharmaceuticals under its new leadership structure.